Fatta B. Nahab

Fatta B. Nahab

Auto-generated profile, based on publicly available information

Fatta B. Nahab

Neuron23 South San Francisco California USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FNFatta B Nahab
Fatta B Nahab
PKPrantik Kundu
Prantik Kundu
CMCarine Maurer
Carine Maurer
QSQian Shen
Qian Shen
MHMark Hallett
Mark Hallett
The sense of agency (SA) is an established framework that refers to our ability to exert and perceive control over our own actions. Having an intact SA provides the basis for the human perception of voluntariness, while impairments in SA are hypothesized to lead to the perception of movements being involuntary that may be seen many neurological or psychiatric disorders. Individuals with functional movement disorders (FMD) experience a lack of control over their movements, yet these movements appear voluntary by physiology. We used fMRI to explore whether alterations in SA in an FMD population could explain why these patients feel their movements are involuntary. We compared the FMD group to a control group that was previously collected using an ecologically valid, virtual-reality movement paradigm that could modulate SA. We found selective dysfunction of the SA neural network, whereby the dorsolateral prefrontal cortex and pre-supplementary motor area on the right did not respond differentially to the loss of movement control. These findings provide some of the strongest evidence to date for a physiological basis underlying these disabling disorders.

23 October 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
GMGabriel M. Moreno
Gabriel M. Moreno
RGRhea Gandhi
Rhea Gandhi
SLStephanie L. Lessig
Stephanie L. Lessig
BWBrenton Wright
Brenton Wright
ILIrene Litvan
Irene Litvan
FNFatta B. Nahab
Fatta B. Nahab

20 May 2021 in Sensors
Verified
Journal Article
Open access
PDF file
JWJeremy Watts
Jeremy Watts
AKAnahita Khojandi
Anahita Khojandi
RVRama Vasudevan
Rama Vasudevan
FNFatta B. Nahab
Fatta B. Nahab
RRRitesh Ramdhani
Ritesh Ramdhani
Parkinson’s disease medication treatment planning is generally based on subjective data obtained through clinical, physician-patient interactions. The Personal KinetiGraph™ (PKG) and similar wearable sensors have shown promise in enabling objective, continuous remote health monitoring for Parkinson’s patients. In this proof-of-concept study, we propose to use objective sensor data from the PKG and apply machine learning to cluster patients based on levodopa regimens and response. The resulting clusters are then used to enhance treatment planning by providing improved initial treatment estimates to supplement a physician’s initial assessment. We apply k-means clustering to a dataset of within-subject Parkinson’s medication changes—clinically assessed by the MDS-Unified Parkinson’s Disease Rating Scale-III (MDS-UPDRS-III) and the PKG sensor for movement staging. A random forest classification model was then used to predict patients’ cluster allocation based on their respective demographic information, MDS-UPDRS-III scores, and PKG time-series data. Clinically relevant clusters were partitioned by levodopa dose, medication administration frequency, and total levodopa equivalent daily dose—with the PKG providing similar symptomatic assessments to physician MDS-UPDRS-III scores. A random forest classifier trained on demographic information, MDS-UPDRS-III scores, and PKG time-series data was able to accurately classify subjects of the two most demographically similar clusters with an accuracy of 86.9%, an F1 score of 90.7%, and an AUC of 0.871. A model that relied solely on demographic information and PKG time-series data provided the next best performance with an accuracy of 83.8%, an F1 score of 88.5%, and an AUC of 0.831, hence further enabling fully remote assessments. These computational methods demonstrate the feasibility of using sensor-based data to cluster patients based on their medication responses with further potential to assist with medication recommendations.

18 April 2023 in Clinical Neurophysiology
Verified
Journal Article
Closed access
ATAntonio I. Triggiani
Antonio I. Triggiani
KSKaya Scheman
Kaya Scheman
SRSarah Pirio Richardson
Sarah Pirio Richardson
MMMasao Matsuhashi
Masao Matsuhashi
EPElizabeth Peckham
Elizabeth Peckham
MHMark Hallett
Mark Hallett

30 July 2019 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PDF file
KLKatherine Longardner
Katherine Longardner
FUFelipe Vial Undurraga
Felipe Vial Undurraga
FNFatta B. Nahab
Fatta B. Nahab
MHMark Hallett
Mark Hallett
DHDietrich Haubenberger
Dietrich Haubenberger
Transducers are defined as any sensor that converts a physiological signal of tremor into an electrical signal. Evolving technologies have utilized transducers to develop devices for tremor measurement that are more convenient, accurate, and capable of continuous recording. Transducer‐based methods provide valuable diagnostic tools for the clinician that can distinguish between different tremor syndromes and differentiate tremor from other hyperkinetic movement disorders. Transducers are also used to objectively quantify and track tremor symptom severity over time and assess clinical response to intervention (e.g., pharmaceutical treatments or DBS). This video highlights the utility of transducer‐based methods in characterizing and quantifying tremor and reviews the available technologies for measuring tremor. We provide case examples that demonstrate how different technology‐based measures for tremor direct the approach to diagnosis and management of symptoms.

27 January 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKatherine Longardner
Katherine Longardner
BWBrenton A Wright
Brenton A Wright
AAAljoharah Alakkas
Aljoharah Alakkas
HYHyeri You
Hyeri You
RXRonghui Xu
Ronghui Xu
FNFatta B Nahab
Fatta B Nahab
Background: Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased mortality in elderly patients with dementia. However, the reasons for higher mortality are unknown. Aim: Expanding on prior work exploring mortality in treated PDP patients, we conducted a retrospective comparison to understand the links between treatment regimen, clinical characteristics, and negative outcomes. Methods: Electronic medical record data extraction included clinically diagnosed PD patients between 4/29/16-4/29/19 and excluded patients with primary psychiatric diagnoses or atypical parkinsonism. Mortality and clinical characteristics during the study period were compared between untreated patients and those receiving pimavanserin, quetiapine, or both agents (combination). Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia. Results: The pimavanserin group (n = 34) had lower mortality than the untreated group (n = 66) (odds ratio = 0.171, 95% confidence interval: 0.025–0.676, p = 0.026). The untreated group had similar mortality compared to the quetiapine (n = 147) and combination (n = 68) groups. All treated groups had a higher LEDD compared to the untreated group, but no other differences in demographics, hospitalizations, medical comorbidities, medications, or laboratory values were found between the untreated and treated groups. Conclusions: PDP patients receiving pimavanserin had lower mortality than untreated patients. We found no other clear differences in clinical characteristics to explain the mortality risk. Prospective randomized trials are needed to definitively identify the optimal PDP treatment regimen and associated risks.